Blinatumomab demonstrates MRD eradication in MRD-positive/chemotherapy-delayed pediatric B-ALL and high response in relapsed/refractory cases: a multicenter cohort study

BackgroundBlinatumomab, a bispecific T-cell engager targeting CD3+ and CD19+, promotes T cell–mediated cytotoxicity against B-cell precursor acute lymphoblastic leukemia (B-ALL). While its efficacy is established in relapsed/refractory (R/R) disease, its role as preemptive therapy for minimal residu...

Popoln opis

Bibliografske podrobnosti

Principais autores:	Na Zhang, Wenting Hu, Yunpeng Dai, Jian Wang, Lijun Qu, Dan Wang, Bingju Liu, Jingbo Shao, Shuhong Shen, Hui Jiang
Format:	Artigo
Jezik:	Inglês
Izdano:	Frontiers Media S.A. 2025-09-01
Serija:	Frontiers in Immunology
Teme:	blinatumomab B-cell acute lymphoblastic leukemia children minimal residual disease relapsed/refractory T cell activation
Online dostop:	https://www.frontiersin.org/articles/10.3389/fimmu.2025.1607138/full
Oznake:	Označite Brez oznak, prvi označite!